Financial Performance - Revenue for the first half of 2023 decreased by 9.73% to RMB 1,120,547,937.20 compared to the same period last year[5] - Net profit attributable to shareholders of the listed company decreased by 17.77% to RMB 329,956,160.32[5] - Basic earnings per share decreased by 26.47% to RMB 0.75[6] - Weighted average return on equity decreased by 11.19 percentage points to 7.81%[6] - Revenue for the period was 1,120,547,937.20 RMB, a decrease of 9.73% compared to the same period last year[80] - Net profit attributable to shareholders was RMB 330 million, down 17.77% compared to the same period last year[92] - Revenue for the first half of 2023 was RMB 1.121 billion, a decrease of 9.73% year-over-year[92] - The company's revenue from nutritional products was 1,053,876,315.45 RMB, with a gross margin of 37.89%, representing a decrease of 11.97% in revenue and a 4.40 percentage point decrease in gross margin compared to the previous year[76] - Revenue from B-vitamins was 980,187,143.87 RMB, with a gross margin of 39.87%, showing a decrease of 10.56% in revenue and a 4.10 percentage point decrease in gross margin compared to the previous year[76] - The company's total revenue was 1,102,324,478.47 RMB, with a gross margin of 37.51%, reflecting a decrease of 9.19% in revenue and a 4.90 percentage point decrease in gross margin compared to the previous year[76] - Domestic sales revenue was 450,389,400.82 RMB, with a gross margin of 38.00%, indicating a 3.24% increase in revenue but a 4.99 percentage point decrease in gross margin compared to the previous year[76] - Export sales revenue was 651,935,077.65 RMB, with a gross margin of 37.17%, showing a decrease of 16.16% in revenue and a 4.91 percentage point decrease in gross margin compared to the previous year[76] Cash Flow and Operating Activities - Cash flow from operating activities increased by 61.77% to RMB 401,420,301.67[5] - Net cash flow from operating activities increased by 61.77% to 401,420,301.67 RMB[80] - Net cash flow from investing activities was 29,091,940.48 RMB, compared to -66,761,791.88 RMB in the same period last year[80] - Financial expenses were -88,546,844.69 RMB, primarily due to increased interest from RMB and USD deposits[79] Assets and Liabilities - Total assets increased by 2.77% to RMB 4,809,368,353.09 compared to the end of last year[5] - Total assets as of June 30, 2023, amounted to 4,809,368,353.09, compared to 4,679,962,858.74 as of December 31, 2022[176] - Cash and cash equivalents increased to 2,363,328,253.22 as of June 30, 2023, from 2,069,864,246.58 as of December 31, 2022[176] - Accounts receivable decreased to 249,343,319.51 as of June 30, 2023, from 259,397,909.74 as of December 31, 2022[176] - Inventory decreased to 397,343,495.17 as of June 30, 2023, from 470,628,636.85 as of December 31, 2022[176] - Fixed assets decreased to 1,153,548,267.87 as of June 30, 2023, from 1,180,323,935.24 as of December 31, 2022[180] - Construction in progress increased to 190,737,514.27 as of June 30, 2023, from 122,640,615.79 as of December 31, 2022[180] - Intangible assets increased to 194,843,819.93 as of June 30, 2023, from 109,814,312.46 as of December 31, 2022[180] - Total current liabilities increased to 380,477,375.20 as of June 30, 2023, from 311,178,261.53 as of December 31, 2022[180] - Accounts payable decreased to 70,058,333.62 as of June 30, 2023, from 108,545,290.36 as of December 31, 2022[180] - Employee benefits payable decreased to 54,777,450.21 as of June 30, 2023, from 99,117,377.05 as of December 31, 2022[180] - The company's monetary funds increased to 2,326,933,446.22 RMB as of June 30, 2023, compared to 2,054,246,268.02 RMB at the end of 2022[182] - Trade receivables decreased slightly to 257,022,544.27 RMB from 261,588,692.80 RMB over the same period[182] - Inventory levels decreased to 406,746,915.52 RMB from 454,808,652.06 RMB[182] - Prepayments increased significantly to 88,675,349.92 RMB from 49,814,225.84 RMB[182] - The company's total liabilities increased to 727,286,341.51 RMB from 621,981,219.02 RMB[197] - Total owner's equity increased to 4,082,082,011.58 RMB from 4,057,981,639.72 RMB[197] - Retained earnings grew to 1,443,478,691.15 RMB from 1,424,346,330.83 RMB[197] - The company's total assets increased to 4,809,368,353.09 RMB from 4,679,962,858.74 RMB[197] - Total current assets increased slightly to 3,177,105,069.57 from 3,171,456,023.36[198] - Long-term equity investments rose significantly to 145,938,705.95 from 50,938,705.95[198] - Fixed assets decreased to 1,068,703,840.22 from 1,092,555,719.72[198] - Construction in progress increased to 170,684,734.47 from 119,851,727.95[198] - Intangible assets grew to 172,988,645.37 from 165,489,853.23[198] - Deferred tax assets increased to 52,147,418.85 from 48,319,829.30[198] - Total non-current assets rose to 1,630,551,142.25 from 1,492,123,966.45[198] - Total assets increased to 4,807,656,211.82 from 4,663,579,989.81[198] - Current liabilities increased to 363,365,589.48 from 294,909,140.99[198] - Short-term borrowings stood at 100,065,000.00[198] Products and Market Position - The company's main products include Vitamin B6, Vitamin B1, Biotin, Folic Acid, Vitamin D3, and Vitamin E powder, primarily used in feed, pharmaceuticals, and food industries[8] - The company has established stable partnerships with thousands of customers, with domestic sales covering all provinces and international sales focusing on Europe, America, and Asia[8] - The company's B-vitamin products are water-soluble and mainly participate in enzyme system activities as coenzymes or cofactors[8] - The company's business is divided into three major segments: B-vitamins, other vitamins, and fine chemical products[8] - The company's global competitiveness is strong, with a diverse product portfolio including Vitamin B6, B1, biotin, folic acid, and other fine chemical products like ABL[21] - The company holds a leading global market share in Vitamin B6 and Vitamin B1, and is in the top tier for biotin and folic acid products[62] - The company has a well-established sales and service network, with products sold in Asia, Europe, North America, South America, Oceania, and Africa[68] Research and Development - The company's R&D efforts are supported by its subsidiary Shanghai Bonasain and its technology center, focusing on product optimization and new product development[66] - R&D expenses increased by 3.58% to 38,417,883.89 RMB[80] - Internal R&D expenditures are classified into research and development phases, with research phase expenses expensed as incurred and development phase expenses capitalized if specific criteria are met[127] Environmental and Social Responsibility - The company has a robust environmental protection system, including wastewater treatment, waste gas management, and hazardous waste treatment facilities[67] - The company has established a comprehensive management system, including quality, environmental, and occupational health and safety management systems, with certifications such as FDA, CEP, and ISO standards[65] - The company's emissions of particulate matter, SO2, and NOX are within the permissible limits, with no instances of exceeding the standards[132] - The company has invested 250,000 yuan in poverty alleviation and rural revitalization projects, benefiting approximately 1,000 people through educational support[137] - The company operates 5 wastewater pretreatment workshops, 3 sewage treatment stations, 2 sets of waste gas treatment systems, and 1 hazardous waste treatment center, all of which are functioning stably[133] - The company has not received any environmental penalties during the reporting period due to non-compliance or inadequate monitoring[133] - The company's VOCs emissions are 12.05mg/m³, which is significantly below the standard limit of 100mg/m³, with an annual emission of 87.36t[152] - CODcr emissions are 39.2mg/m³, below the final direct discharge standard of 60mg/L, with an annual emission of 119.8t[152] - Ammonia nitrogen emissions are 0.84mg/m³, well below the final direct discharge standard of 8mg/L, with an annual emission of 16.17t[152] - Particulate matter emissions from the thermal power plant are 1.97mg/m³, below the standard limit of 10mg/m³, with an annual emission of 10.18t[152] - SO₂ emissions from the thermal power plant are 11.82mg/m³, below the standard limit of 35mg/m³, with an annual emission of 10.72t[152] - NOX emissions from the thermal power plant are 23.73mg/m³, below the standard limit of 50mg/m³, with an annual emission of 50.89t[152] - The company has implemented energy-saving measures, including new equipment and technologies, resulting in a reduction in energy consumption per unit of main products[158] - The company has established a comprehensive environmental management system and passed environmental management system certification[157] - The company conducts regular environmental monitoring using both manual and online methods, with data uploaded in real-time to environmental authorities[155] - The company has developed an emergency response plan for environmental incidents, which was filed with the local environmental bureau in April 2021[154] Shareholder and Equity Information - The company distributed RMB -310,823,800.00 to shareholders during the period[19] - Total owner's equity increased by RMB 405,522,820.10, with retained earnings growing by RMB 400,554,808.56[19] - Owner's equity at the end of the period was RMB 4,082,082,011.58, with a capital reserve of RMB 1,981,933,320.43[25] - Comprehensive income for the period was RMB 401,248,794.80, contributing to the increase in owner's equity[25] - The company's total registered capital is RMB 437.78 million, with a total share capital of 437.78 million shares, each with a par value of RMB 1[34] - The company has seven subsidiaries included in its consolidated financial statements, such as Lepingshi Tianxin Thermal Power Co., Ltd. and Shanghai Bonasain Pharmaceutical R&D Co., Ltd[35] - The company recorded a total of 4,968,011.54 in equity-based compensation for the period[43] - The total equity balance at the end of the period was 2,314,914,198.45[45] - Comprehensive income for the period totaled 400,554,808.56 RMB[46] - Owner's capital contributions and reductions amounted to 4,968,011.54 RMB, primarily from share-based payments[46] - The ending balance for the period was 2,304,976,059.61 RMB[46] - The beginning balance of owner's equity was 4,063,022,747.23 RMB[48] - Total comprehensive income for the period was 344,607,638.98 RMB[48] - Owner's capital contributions and reductions were 4,968,011.54 RMB, mainly from share-based payments[48] - Profit distribution included a reduction of 310,823,800.00 RMB[48] - The beginning balance of consolidated owner's equity was 4,057,981,639.72 RMB[56] - Total comprehensive income for the period was 329,956,160.32 RMB[56] - Owner's capital contributions and reductions were 4,968,011.54 RMB[56] - The largest shareholder, Xu Jiangnan, holds 203,603,970 restricted shares with a lock-up period until January 11, 2026[195] - The second-largest shareholder, Xu Jing, holds 59,110,830 restricted shares with the same lock-up period[195] - The company's largest shareholder, Xu Jiangnan, holds 203,603,970 shares, representing 46.51% of the total shares, all of which are restricted shares[150] - Xu Jing, the second-largest shareholder, holds 59,110,830 shares, accounting for 13.50% of the total shares, all of which are restricted shares[150] - Wang Guangtian, the third-largest shareholder, holds 56,803,200 shares, representing 12.98% of the total shares, all of which are restricted shares[150] - Qiu Qinyong, the fourth-largest shareholder, holds 35,502,000 shares, accounting for 8.11% of the total shares, all of which are restricted shares[150] - The company has committed to stabilizing its stock price within three years of listing by implementing a stock repurchase plan if the stock price falls below the net asset value per share for 20 consecutive trading days[145] - The controlling shareholder and actual controller have pledged to support the stock price stabilization plan by voting in favor of stock repurchase proposals and increasing their shareholdings if necessary[145] - The company has established a lock-up period of 36 months for shares held by certain entities, during which they cannot transfer or entrust others to manage the shares[142] - After the lock-up period, shareholders are allowed to reduce their holdings, but they must announce the reduction three trading days in advance and comply with relevant laws and regulations[142] - If the stock price falls below the issue price for 20 consecutive trading days within six months of listing, the lock-up period for certain shares will be automatically extended by at least six months[142] - The company has committed to avoiding competition with its subsidiaries and will transfer any competing business opportunities to the subsidiaries or third parties to eliminate potential conflicts[145] - The company has committed to not transferring or entrusting others to manage its directly or indirectly held shares before the IPO for 36 months from the listing date[164] - The company will strictly regulate related-party transactions with its wholly-owned, controlled subsidiaries, and other entities under actual control[164] - The company will follow fair, just, and open principles for unavoidable related-party transactions, signing relevant agreements and fulfilling decision-making and disclosure obligations[164] - The company ensures that all transactions with its subsidiaries and controlled entities will strictly follow market rules and commercial principles[164] - The company will avoid using its controlling shareholder status to harm the interests of the company and other shareholders through related-party transactions[164] - The company will not directly or indirectly borrow, occupy, or otherwise misappropriate the company's funds or assets[164] - The company has disclosed all equity or interests held directly or indirectly in other enterprises or economic organizations[165] - The company and its controlled entities will not engage in any business activities that compete directly or indirectly with the company's main business[165] - The company will ensure that its controlled entities do not seek commercial opportunities belonging to the company or its subsidiaries[165] - The company will take necessary measures to correct and remedy any violations of the above commitments and bear compensation for any losses caused[165] - The company has committed to avoiding any business activities that directly or indirectly compete with Tianxin Pharmaceutical, including ceasing sales of similar products and not engaging in any competitive business opportunities[167] - The company will not provide business qualifications, operating licenses, proprietary technologies, sales channels, or customer information to any entities that compete with Tianxin Pharmaceutical[167] - The company will reduce and regulate related-party transactions with Tianxin Pharmaceutical, ensuring they are conducted at fair market prices and in compliance with legal and regulatory requirements[168] Legal and Compliance - The company has no significant litigation or arbitration matters during the reporting period[170] - The company and its controlling shareholders are not involved in any illegal activities or subject to penalties, and there are no significant debts overdue[170] Investments and Capital Expenditures - Investment in the first half of 2023 was RMB 104.5 million, a 1507.69% increase compared to the same period last year[96] - The company's subsidiary, Ningxia Tianxin Pharmaceutical Co., Ltd., is investing RMB 890 million in a fine chemical products and supporting thermal power project[99] - The company's trading financial assets decreased by 100% due to the redemption of financial products[93] - Other current assets decreased by 67.40% due to a reduction in VAT credits[93] - Construction in progress increased by 55.53% due to increased engineering investments[93] - Intangible assets grew by 77.43% due to the acquisition of new land use rights[93] - Other non-current assets increased by 180.98% due to prepayments for long-term

一、 2023年第二季度主要经营数据 1、主营业务分产品情况 证券代码：603235 证券简称：天新药业 公告编号：2023-020 江西天新药业股份有限公司 关于 2023 年第二季度经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号——行 业信息披露》的相关规定，现将江西天新药业股份有限公司（以下简称"公司"） 2023 年第二季度经营数据（未经审计）公告如下： | 产品分类 | 2023 | 年 4-6 | 月收入 | 2022 | 年 4-6 | 月收入 | 同比变动 | | --- | --- | --- | --- | --- | --- | --- | --- | | 内销 | | 234,152,402.71 | | | 204,141,804.45 | | 14.70% | | 外销 | | 298,477,236.68 | | | 418,340,681.10 | | -28.65% | | 小计 | | 532,629,639. ...

证券代码：603235 证券简称：天新药业 公告编号：2023-018 江西天新药业股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 董事会会议召开情况 江西天新药业股份有限公司（以下简称"公司"）第二届董事会第十五次会议 于 2023 年 8 月 24 日在公司会议室以现场结合通讯表决的方式召开。本次会议通 知已于 2023 年 8 月 14 日以电子邮件及专人送达等方式送达全体董事。本次会议 应到董事 9 人，实到董事 9 人。会议由公司董事长许江南先生主持，公司监事、 高级管理人员列席会议。本次会议的召开符合《中华人民共和国公司法》《江西 天新药业股份有限公司章程》等有关规定，会议决议合法有效。 二、 董事会会议审议情况 （一）审议通过《关于公司 2023 年半年度报告及其摘要的议案》 该议案同意票数为 9 票，反对票数为 0 票，弃权票数为 0 票。 1 （三）审议通过《关于使用闲置自有资金进行现金管理的议案》 该议案同意票数为 9 票，反对票数为 0 票，弃权票数为 ...

二、监事会会议审议情况 （一） 审议通过《关于公司 2023 年半年度报告及其摘要的议案》 该议案同意票数为 3 票，反对票数为 0 票，弃权票数为 0 票。 江西天新药业股份有限公司 第二届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 证券代码：603235 证券简称：天新药业 公告编号：2023-019 江西天新药业股份有限公司（以下简称"公司"）第二届监事会第十三次会议 于 2023 年 8 月 24 日在公司会议室以现场表决的方式召开。本次会议通知已于 2023 年 8 月 14 日以电子邮件及专人送达等方式送达全体监事。本次会议应到监 事 3 人，实到监事 3 人。会议由公司监事会主席章根宝先生主持，公司董事会秘 书列席本次会议。本次会议的召开符合《中华人民共和国公司法》《江西天新药 业股份有限公司章程》（以下简称"《公司章程》"）等有关规定，会议决议合 法有效。 （3）公司《2023 年半年度报告》及摘要所披露的信息真实、准确、完 整，承诺其中不存在虚假记载、误 ...

中信证券股份有限公司 关于江西天新药业股份有限公司 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江西天 新药业股份有限公司（以下简称"天新药业"或"公司"）首次公开发行股票并 上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所上市 公司自律监管指引第 11 号——持续督导》《上市公司监管指引第 2 号——上市 公司募集资金管理和使用的监管要求》《上海证券交易所上市公司募集资金管理 办法》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有关规 定，对天新药业使用闲置募集资金进行现金管理的事项进行了专项核查，核查情 况如下： 一、使用闲置募集资金进行现金管理的基本情况 （一）投资目的 为充分发挥募集资金使用效率、适当增加收益，在确保不影响公司正常经营、 不影响募集资金项目建设和募集资金使用计划的前提下，公司使用部分暂时闲置 募集资金进行现金管理。 （二）投资金额 本次进行现金管理的资金来源为公司闲置募集资金，额度为不超过人民币 8 亿元。在上述额度内，公司可以循环滚动使用。 （三）资金来源及相关情况 本次进行现金管理的资金来源为公司闲置募集资金。 经中国证券监督管理委 ...

证券代码：603235 证券简称：天新药业 公告编号：2023-023 单位：人民币万元 | | | | 1 | 中国工商银行股份有限公司乐平支行 | 1503229029000281830 | 23,886.55 | | --- | --- | --- | --- | | 2 | 中国建设银行股份有限公司乐平支行 | 36050162025009006666 | 16,002.13 | | 3 | 上饶银行股份有限公司乐平支行 | 231103090000022665 | 7,705.48 | | 4 | 招商银行股份有限公司景德镇分行 | 798900353010808 | 1,000.00 | | 5 | 中国银行股份有限公司乐平支行 | 191753982539 | 42,235.62 | | 6 | 中国银行股份有限公司乐平支行 | 202253980612 | 63,129.15 | | | 合计 | | 153,958.93 | 本公司本次发行募集资金总额为人民币 161,460.64 万元，发行费用总额为人 民币 9,737.33 万元（不含税），具体如下： 江西天新药业股份有限公司 关于 2 ...

根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易 所股票上市规则》《上海证券交易所上市公司自律监管指引第1号 -- 规范运作》 《上市公司独立董事规则》以及《江西天新药业股份有限公司章程》(以下简称 《公司章程》）《江西天新药业股份有限公司独立董事工作制度》等相关法律法 规、规章制度的规定,我们作为公司的独立董事,经认真审阅公司第二届董事会 第十五次会议相关文件,听取相关说明,基于独立、客观、公正的判断立场，发 表独立意见如下: 江西天新药业股份有限公司独立董事 关于第二届董事会第十五次会议相关事项的独立意见 一、关于公司使用闲置募集资金进行现金管理的独立意见 经过认真审查,我们认为: 公司本次使用闲置募集资金不超过 8 亿元进行现金管理,董事会审议的表决 程序合法、有效，符合公司当前的实际情况，有利于公司的持续稳定健康发展, 有利于提高公司资金的使用效率,获得一定的投资收益,符合《上市公司监管指 引第 2 号——上市公司募集资金管理和使用的监管要求(2022年修订)》等法 律、法规以及规范性文件和《公司章程》《江西天新药业股份有限公司募集资金 管理制度》的相关规定,不存在变相改变募集资金投 ...

证券代码：603235 证券简称：天新药业 公告编号：2023-021 江西天新药业股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好、短期（不超过 12 个月）的投资产品。 投资金额：最高额不超过人民币 8 亿元（含本数，下同），在上述额度内 可循环滚动使用。 已履行的审议程序：江西天新药业股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日召开公司第二届董事会第十五次会议和第二届监事会第十三次 会议，会议审议通过《关于使用闲置募集资金进行现金管理的议案》，同意使用 不超过 8 亿元闲置募集资金进行现金管理。公司独立董事对该议案发表了明确同 意的独立意见。此议案无需提交公司股东大会审议。 特别风险提示：公司拟进行现金管理投资产品为风险较低的投资产品， 但金融市场受宏观经济、财政及货币政策影响较大，公司拟进行现金管理投资产 品可能受到市场波动的影响，投资收益存在不确定性。 江西天新药业股份有限公司（以下简称"公司"）于 ...

证券代码：603235 证券简称：天新药业 公告编号：2023-022 投资种类：安全性高、流动性好的投资产品。 投资金额：最高额不超过人民币 15 亿元（含本数，下同），在上述额度 内公司及子公司可循环滚动使用。 已履行的审议程序：江西天新药业股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日召开公司第二届董事会第十五次会议和第二届监事会第十三次 会议，会议审议通过《关于使用闲置自有资金进行现金管理的议案》，同意使用 不超过 15 亿元闲置自有资金进行现金管理。此议案无需提交公司股东大会审议。 特别风险提示：公司拟进行现金管理投资产品为风险较低的投资产品， 但金融市场受宏观经济、财政及货币政策影响较大，公司拟进行现金管理投资产 品可能受到市场波动的影响，投资收益存在不确定性。 江西天新药业股份有限公司（以下简称"公司"）于 2023 年 8 月 24 日召开 的第二届董事会第十五次会议及第二届监事会第十三次会议审议通过了《关于使 用闲置自有资金进行现金管理的议案》，公司及子公司拟使用最高额度不超过人 民币 15 亿元的闲置自有资金进行现金管理，适时向各金融机构购买安全性高、 流动性好、短期的 ...

证券代码：603235 证券简称：天新药业 公告编号：2023-016 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 05 月 31 日(星期三) 下午 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 24 日(星期三) 至 05 月 30 日(星期 二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱 ir@txpharm.com 进行提问。公司将在说明会上对投资者 普遍关注的问题进行回答。 江西天新药业股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日发布公司 2022 年年度报告，并于 2023 年 4 月 29 日发布公司 2023 年第一季度报告，为便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 ...